- Home
- AIP vs CRDF Comparison
AIP vs CRDF Comparison
Compare AIP & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIP
- CRDF
- Stock Information
- Founded
- AIP 2003
- CRDF 1999
- Country
- AIP United States
- CRDF United States
- Employees
- AIP N/A
- CRDF N/A
- Industry
- AIP Semiconductors
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIP Technology
- CRDF Health Care
- Exchange
- AIP Nasdaq
- CRDF Nasdaq
- Market Cap
- AIP 277.9M
- CRDF 240.2M
- IPO Year
- AIP 2021
- CRDF N/A
- Fundamental
- Price
- AIP $11.48
- CRDF $3.45
- Analyst Decision
- AIP Strong Buy
- CRDF Strong Buy
- Analyst Count
- AIP 4
- CRDF 3
- Target Price
- AIP $13.00
- CRDF $10.33
- AVG Volume (30 Days)
- AIP 362.4K
- CRDF 1.4M
- Earning Date
- AIP 02-18-2025
- CRDF 02-27-2025
- Dividend Yield
- AIP N/A
- CRDF N/A
- EPS Growth
- AIP N/A
- CRDF N/A
- EPS
- AIP N/A
- CRDF N/A
- Revenue
- AIP $54,739,000.00
- CRDF $688,000.00
- Revenue This Year
- AIP $8.13
- CRDF $25.03
- Revenue Next Year
- AIP $19.08
- CRDF N/A
- P/E Ratio
- AIP N/A
- CRDF N/A
- Revenue Growth
- AIP 4.53
- CRDF 49.57
- 52 Week Low
- AIP $5.03
- CRDF $1.44
- 52 Week High
- AIP $12.64
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- AIP 61.08
- CRDF 45.05
- Support Level
- AIP $10.50
- CRDF $3.33
- Resistance Level
- AIP $12.13
- CRDF $4.89
- Average True Range (ATR)
- AIP 0.82
- CRDF 0.31
- MACD
- AIP -0.04
- CRDF -0.15
- Stochastic Oscillator
- AIP 59.55
- CRDF 10.56
About AIP Arteris Inc.
Arteris Inc is a developer of on-chip interconnect fabric technology designed for a variety of devices and in the development and distribution of Network-on-Chip (NoC) interconnect intellectual property (IP). The company's technology is used in System-on-Chip (SoC) and provides software and services to automate SoC integration, enabling users to efficiently deploy NoC IP, and offer IP support, maintenance services, professional services, and training and on-site support services. The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").